Wedbush Maintains Neutral on Ultragenyx Pharmaceutical, Lowers Price Target to $22
Benzinga Newsdesk 5 hours ago
Analyst RatingsNewsPrice Target
Wedbush analyst Laura Chico maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Neutral and lowers the price target from $25 to $22.
Wedbush analyst Laura Chico maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Neutral and lowers the price target from $25 to $22.